Advanced Cardiovascular Systems, Inc.

Abbott Cardiovascular Systems, Inc.

Connie S Kwok

Charles David Claude

Stephen D Pacetti

Eugene T Michal

Thierry Glauser

Syed Faiyaz Ahmed Hossainy

Lothar W Kleiner

Yiwen Tang

Irina Astafieva

Ashok A Shah

John Whatley

Gene Michal

Jihong Qu

Shamim M Malik

Sophia W Liao

Michael Seegmiller

Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

Hyaluronic acid based copolymers

Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1-lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1-lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PR11, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

Hydrogel bioscaffoldings and biomedical device coatings

Provided herein re a composition and a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Coating compositions and coatings for medical devices containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer

A segmented polyurethane and an amphiphilic random or block copolymer are disclosed. The segmented polyurethane and the amphiphilic random or block copolymer can be used for fabricating a coating for an implantable medical device such as a stent.

Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same

Provided herein are a method, which comprises implanting in a patient an implantable device comprising a coating that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Merhods of treatment with devices having a coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer

A method for local delivery of a drug is provided. The method comprises acts of: (a) implanting a medical device including a drug-containing coating in a patient for the delivery of the drug, wherein the coating comprises a drug and a polymer; and (b) applying an electric current for an interval of time to the topcoat to cause the polymer to transform from a crystalline structure to an amorphous structure so as to increase the rate of release of the drug during the time interval, wherein after the electric current is terminated, the crystallinity of the polymer returns back to essentially the same degree of crystallinity or a more crystalline structure than that of when the polymer was exposed to the current.

Methods of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure

A method for local delivery of a drug is provided. The method comprises the acts of (a) implanting a medical device carrying a drug-containing coating in a patient for the sustained local delivery of the drug, wherein at least a portion of the coating is transformed from crystalline structure to amorphous structure; and (b) applying an electric current for an interval of time to the device for increasing the rate of release of the drug, wherein the coating is further transformed from crystalline structure to amorphous structure; and (c) terminating the current after an interval of time, wherein at least a portion of the amorphous structure in the coating is at least partially restored to crystalline structure.

Method of delivering a drug using a medical device with a coating comprising a self-assembled molecular structure

Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer

A coating for an implantable medical device is disclosed, the coating including a self-assembled molecular structure. The coating can be used for altering the release rate of a therapeutic substance from the implantable device.

Coatings comprising self-assembled molecular structures

An apparatus for plasma polymerize coating of medical devices, such as stents, is disclosed. A method for forming plasma-polymerized coating for implantable medical devices is also disclosed.

Growing community of inventors

Santa Clara, CA, United States of America

Connie S Kwok